

Enbrel (etanercept)
Effective 03/01/2025

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Exceptions	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Enbrel (etanercept) is a tumor necrosis factor (TNF) blocker indicated for the treatment of adults with:

- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Plaque psoriasis

It is also approved in pediatric patients with:

- Polyarticular juvenile idiopathic arthritis (pJIA), 2 years of age and older
- Juvenile psoriatic arthritis, 2 years of age and older
- Plaque psoriasis, 4 years of age and older

Coverage Guidelines

Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted when all the following diagnosis-specific criteria are met:

Moderately to severely active rheumatoid arthritis (RA)

1. Diagnosis of moderately to severely active rheumatoid arthritis
2. The member has a minimum duration of 3-month trial and failure, contraindication, or intolerance to ONE of the following conventional therapies at maximally tolerated doses:
 - a. Methotrexate
 - b. Leflunomide
 - c. Sulfasalazine

Moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA)

1. Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA)
2. The member has a minimum duration of 6-week trial and failure, contraindication, or intolerance to ONE of the following conventional therapies at maximally tolerated doses
 - a. Leflunomide
 - b. Methotrexate

Active psoriatic arthritis (PsA)

1. Diagnosis of active psoriatic arthritis
2. The member meets ONE of the following:
 - a. Actively inflamed joints
 - b. Dactylitis
 - c. Enthesitis
 - d. Axial disease
 - e. Active skin and/or nail involvement

Active ankylosing spondylitis (AS)

1. Diagnosis of active ankylosing spondylitis
2. Member has minimal duration of 1-month trial and failure, contraindication, or intolerance to TWO different non-steroidal anti-inflammatory drugs (NSAIDs) at maximally tolerated doses.

Moderate to severe chronic plaque psoriasis (PsO)

1. Diagnosis of moderate to severe chronic plaque psoriasis
2. Member has at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected
3. Member meets ONE of the following criteria:
 - a. Minimum duration of 4-week trial and failure, contraindication, or intolerance to ONE of the following topical therapies
 - I. Corticosteroids (e.g., betamethasone, clobetasol)
 - II. Vitamin D analogs (e.g., calcitriol, calcipotriene)
 - III. Tazarotene
 - IV. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
 - V. Anthralin
 - VI. Coal tar
 - b. Member has severe psoriasis that warrants a biologic DMARD as first-line therapy.

Continuation of Therapy

Requests for reauthorizations for all diagnoses will be granted when the following criteria are met:

1. Documentation is submitted supporting improvement in member's condition as evidenced by low disease activity or improvement in signs and symptoms of the condition.

Limitations

1. Approvals will be granted for 24 months.

References

1. Elmets CA, Korman NJ, Farley Prater E, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 2021;84:432-70.



2. Enbrel (etanercept) [prescribing Information]. Thousand Oaks, CA: Amgen; October 2023.
3. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. 2021;73(7):924-939.
4. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029-72.
5. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol. 2019;71(6):846-863.
6. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5-32.
7. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2015;68(1):1-25.
8. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599-1613.

Review History

03/21/2005 – Reviewed

05/15/2005 – Effective

02/27/2006 – Reviewed

02/25/2008 – Reviewed

02/23/2009 – Reviewed

02/22/2010 – Reviewed

02/28/2011 – Reviewed

02/27/2012 – Reviewed

02/25/2013 – Reviewed

02/24/2014 – Reviewed

02/23/2015 – Reviewed

02/22/2016 – Reviewed

02/2017 – Reviewed (switched to SGM)

02/26/2018 – Reviewed (switched to Custom) in P&T Meeting

02/20/2019 – Reviewed

07/22/2020 – Reviewed and updated July P&T Mtg; reworded overview; removed compendial use of reactive arthritis; changed diagnosis of axial spondyloarthritis to nonradiographic axial spondyloarthritis. Effective 10/01/2020.

11/15/2023 – Reviewed and Updated for November P&T; removed TB requirement. Added additional treatment options for conventional therapies for Rheumatoid arthritis. Added additional treatment options for 6-week treatment for PJI. Psoriatic arthritis – removed conventional therapies and added member meets one of the following: actively inflamed joints, dactylitis, enthesitis, axial disease, or active skin and/or nail involvement. Plaque psoriasis – changed from 5% BSA to 3% BSA. Removed appendix with contraindications to methotrexate. Consolidated conventional therapies for plaque psoriasis. Removed Appendix. Effective 1/1/24.

10/09/2024 – Reviewed and updated for October P&T. Updated reauthorization criteria language to be consistent with other immunomodulators. Effective 1/1/2025.

12/11/2024 – Reviewed and updated for December P&T. Removed diagnosis of nonradiographic axial spondyloarthritis. Effective 3/1/2025.

